Provention Bio (PRVB) 10-Q2021 Q1 Quarterly report

Filed: 6 May 21, 7:27am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AAV, ACA, acknowledging, addressing, advice, aggressively, analytical, Andrew, answer, argued, argument, await, Azar, Biden, biotherapeutic, borrow, borrowing, Budget, campaign, China, CHMP, CMO, collateralized, Comparison, conclusion, confirmatory, consecutive, constitutionality, content, context, correct, delete, devastating, Drechsler, duly, EEA, elucidate, emphasized, encoding, enzyme, epidemiological, ERP, Exhibit, expenditure, explicitly, facilitate, feedback, feet, field, formatted, forward, fulfill, GAA, glycogen, guaranty, Hangzhou, headcount, hereof, herewith, Hong, Huadong, IgM, ILAP, implicit, implicitly, inactivated, incremental, Inline, input, Inspector, iXBRL, judgement, Kong, led, length, lessee, lessor, letter, lymphocyte, MAA, Macau, mainland, mandate, mandated, marker, mention, MHRA, mice, mission, modality, mouse, muscle, NaN, OOPD, opt, outset, Passport, path, PD, peer, people, pertaining, pharmacokinetic, pharmacology, pharmacy, PK, plasma, Pompe, Portability, proceed, rationale, ready, referral, reiterated, remediation, residual, resource, secondary, sensitivity, skeletal, solution, sought, square, standalone, sublease, subsidiary, suggest, suggested, supplementary, Supreme, surrogate, Taiwan, telehealth, thereunto, transgenic, transient, treatable, UK, undersigned, understood, undiagnosed, unsuccessful, upcoming, upstream, vector, vendor, voucher, wake, Zhongmei

Removed: activation, adjust, administered, aimed, approach, BTD, circulating, closing, collective, combat, confirm, converted, coxsackie, customary, dated, delivered, deplete, dialogue, differentiation, enhanced, enrolled, Exchanged, harbor, holding, initiative, interception, intravenously, kind, LLC, module, multidisciplinary, NIDDK, NIH, official, oral, percent, pharmacodynamic, profound, PULSE, ratably, relapse, revise, rolling, sublicense, undergoing, undue

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated PRVB transcripts

PRVB similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Provention Bio, Inc. (“Provention Bio”) on Form 10-Q for the quarterly period ending March 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on the date hereof (the “Report”), I, Andrew Drechsler, Chief Financial Officer of Provention Bio, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Provention Bio.

Date: May 6, 2021

	/s/ Andrew Drechsler
	Andrew Drechsler
	Chief Financial Officer